Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of parkinson's disease

Journal of the American College of Nutrition

Volumn 26, Issue 4, 2007, Pages 341-349

  Datla, Krishna P ^a   Zbarsky, Virginia ^a   Rai, Deepal ^a   Parkar, Shabnam ^a   Osakabe, Naomi ^c   Aruoma, Okezie I ^b,d   Dexter, David T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SOUTH BANK UNIVERSITY   (United Kingdom)

^c MEIJI DAIRIES CORPORATION   (Japan)

^d Seoul National University   (South Korea)

Author keywords

6 hydroxydopamine; Flavonoids; Neuroprotection; Ntioxidants; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ANTIOXIDANT; FLAVONOID; HOMOVANILLIC ACID; ISOFLAVONE DERIVATIVE; NEUROTOXIN; OXIDOPAMINE; PLANT EXTRACT; PROCYANIDIN; SCAVENGER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACAO; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOPAMINERGIC NERVE CELL; INFLAMMATION; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; RED CLOVER; SUBSTANTIA NIGRA; TANGERINE;

ANIMALS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOPAMINE; FLAVONOIDS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHYTOTHERAPY; PLANT EXTRACTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

ANIMALIA; CITRUS RETICULATA; RATTUS; THEOBROMA CACAO; TRIFOLIUM PRATENSE; VITACEAE;

EID: 35348924274     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2007.10719621     Document Type: Article

References (80)

1. de Rijk MC, Tzourio C, Breteler, MMB, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA: Prevalence of parkinsonism and Parkinson’s disease in Europe. The EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 62:10–15, 1997.
2. Pakkenberg B, Moller A, Gundersen HJG, Dam AM, Pakkenberg H: The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54:30–33, 1991.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455, 1973.
4. Jenner P: Oxidative mechanisms in nigral cell death in Parkinson’s disease. Mov Disord 13:24–34, 1998.
5. Olanow CW, Tatton WG: Etiology and pathogenesis of Parkinson’s disease. Ann Rev Neurosci 22:123–144, 1999.
6. Bains JS, Shaw CA: Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 25:335–358, 1997.
7. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD: Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389, 1989.
8. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y: Immunohistochemical detection of 4-hydroxynonenol protein adducts in Parkinson’s disease. Proc Natl Acad Sci USA 93:2696–2701, 1996.
9. Alam ZI, Daniel SE, Lees AJ, Marsden CD, Jenner P, Halliwell B: A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69: 1326–1329, 1997.
10. Sanchez-Ramos JR, Overik E, Ames BN: A marker of oxyradicalmediated DNA damage (8-hydroxy-2’ deoxyguanosine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3:197–204, 1994.
11. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B: Oxidative DNA damage in the parkinsonian brain: an apparent increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69:1196–1203, 1997.
12. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ: Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154:1423–1429, 1999.
13. Golbe LI, Farrell TM, Davis PH: Case-control study of early dietary factors in Parkinson’s disease. Arch Neurol 45:1350–1353, 1988.
14. de Rijk MC, Breteler MMB, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FGA, Hofman A: Dietary antioxidants and Parkinson’s disease. The Rotterdam study. Arch Neurol 54:762–765, 1997.
15. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. New Engl J Med 328:176–183, 1993.
16. Fahn S: A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32:S128–S132, 1992.
17. Whone AL, Watts RL, Stoessl J, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ: Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93–101, 2003.
18. Iida M, Miyazaki I, Tanaka K-I, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51–59, 1999.
19. Drukarch B, van Muiswinkel FL: Drug treatment of Parkinson’s disease. Time for phase II. Biochem Pharmacol 59:1023–1031, 2000.
20. van Acker SABE, van Balen GP, van den Berg D-J, Bast A, van der Vijgh WJF: Influence of iron chelation on the antioxidant activity of flavonoids. Biochem Pharmacol 56:935–943, 1998.
21. Yamaguchi F, Yoshimura Y, Nakazawa H, Ariga T: Free radical scavenging activity of grape seed extract and antioxidants by electron spin resonance spectrometry in an H2O2/NaOH/DMSO system. J Agric Food Chem 47:2544–2548, 1999.
22. Ishiwa J, Sato T, Mimaki Y, Sashida Y, Yano M, Ito A: A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol 27:20–25, 2000.
23. Roychowdhury S, Wolf G, Keilhoff G, Bagchi D, Horn T: Protection of primary glial cells by grape seed proanthocyanidin extract against nitrosative/oxidative stress. Nitric Oxide: Biol Chem 5:137–149, 2001.
24. Pietta P-G: Flavonoids as antioxidants. J Nat Prod 63:1035–1042, 2000.
25. O’Leary KA, de Pascual-Tereasa S, Needs PW, Bao Y-P, O’Brien NM, Williamson G: Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcrition. Mutation Res 551:245–254, 2004.
26. Heijnen CGM, Haenen GRMM, Vekemans JAJM, Bast A: Peroxynitrite scavenging of flavonoids: structure activity relationship. Environ Toxicol Pharmacol 10:199–206, 2001.
27. Ishige K, Schubert D, Sagara Y: Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Rad Biol Med 30:433–446, 2001.
28. Sano A, Yamakoshi J, Tokutake S, Tobe K, Kubota Y, Kikuchi M: Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. Biosci Biotechnol Biochem 67:1140–1143, 2003.
29. Mandel S, Youdim MBH: Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Rad Biol Med 37:304–317, 2004.
30. Scalbert A, Morand C, Manach C, Remesy C: Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother 56: 276–282, 2002.
31. Matsuoka Y, Hasegawa H, Okuda S, Muraki T, Uruno T, Kubota K: Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries. J Pharmacol Exp Ther 274:602–608, 1995.
32. Pelzer LE, Guardia T, Juarez AO, Guerreiro E: Acute and chronic anti-inflammatory effects of plant flavonoids. Il Farmaco 53:421–424, 1998.
33. Di Carlo G, Mascolo N, Izzo AA, Capasso F: Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 65:337–353, 1999.
34. Murakami A, Nakamura Y, Ohto Y, Yano M, Koshiba T, Koshimizu K, Tokuda H, Nishino H, Ohigashi H: Suppressive effects of citrus fruits on free radical generation and nobiletin, an antiinflammatory polymethoxyflavonoid. Biofactors 12:187–192, 2000.
35. Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT: Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson’s disease. Neuroreport 12:3871–3875, 2001.
36. Paxinos G, Watson C: “The Rat Brain in Stereotaxic Coordinates,” 2nd ed. London: Academic Press 1986.
37. Murray HE, Pillai AV, Mcarthur SR, Razvi N, Datla KP, Dexter DT, Gillies GE: Dose-and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathways of adult rats: differential actions of estrogen in males and females. Neuroscience 116:213–222, 2003.
38. Carman LS, Gage FH, Shults CW: Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 553:275–283, 1991.
39. Sarre S, Yuan H, Jonkers N, van Hemelrijck A, Ebinger G, Michotte Y: In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 90:29–39, 2004.
40. Datla KP, Blunt SB, Dexter DT: Chronic L-DOPA administration is not toxic to the remaining nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions. Mov Disord 16:424–434, 2001.
41. Ungerstedt U, Arbuthnott GW: Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopaminergic system. Brain Res 24:485–493, 1970.
42. Marshall JF, Ungerstedt U: Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur J Pharmacol 41:361–367, 1977.
43. Heikkila R, Cohen G: Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Potentiation by ascorbic acid. Mol Pharmacol 8:241–248, 1972.
44. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL: Autooxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem 74:1605–1612, 2000.
45. Saner A, Thoenen H: Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 7:147–154, 1971.
46. Cohen G, Heikkila RE: The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249:2447–2452, 1974.
47. Glinka YY, Youdim MB: Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 292:329–332, 1995.
48. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW: Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660:8–18, 1994.
49. He Y, Lee T, Leong SK: Time course of dopaminergic cell death and changes in iron, and transferring levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning. Free Rad Res 31:103–112, 1999.
50. Akiyama H, McGeer P: Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 489:247–253, 1989.
51. Rogove AD, Triska SE: Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 8:19–25, 1997.
52. Yasuda T, Yoshimura Y, Yabuki H, Nakazawa T, Ohsawa K, Mimaki Y, Sashida Y: Urinary metabolites of nobiletin orally administered to rats. Chem Pharm Bull 51:1426–1428, 2003.
53. van Acker SABE, van den Berg D-J, Tromp MNJL, Griffioen DH, van Bennekom WP, van der Vijgh WJF, Bast A: Structural aspects of antioxidant activity of flavonoids. Free Rad Biol Med 20:331–342, 1996.
54. Rice-Evans CA, Miller NJ, Paganga G: Structure-activity relationships of flavonoids and phenolic acids. Free Rad Biol Med 20: 933–956, 1996.
55. Benavente-Garcia O, Castillo J, Marin FR, Ortuno A, Del Rio JA: Uses and properties of citrus flavonoids. J Agric Food Chem 45:4505–4515 1997.
56. Waterhouse AL, Shirley JR, Donovan JL: Antioxidants in chocolate. Lancet 348:834, 1996.
57. Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, Gebhardt S, Prior RL: Concentrations of proanthocyanidins in common foods and estimations of normal consumption. J Nutr 134:613–617, 2004.
58. Baba S, Osakabe N, Natsume M, Terao J: Absorption and urinary excretion of procyanidins B2 [epicatechin-(4β-8)-epicatechin] in rats. Free Rad Biol Med 33:142–148, 2002.
59. Hatano T, Miyatake H, Natsume M, Osakabe N, Takizawa T, Ito H, Yoshida T: Proanthocyanidin glycosides and related polyphenols from cocoa liquor and their antioxidant effects. Phytochem 59:749–758, 2002.
60. Bors W, Michel C, Stettmaier K: Electron paramagnetic resonance studies of radical species of proanthocyanidins and gallate esters. Arch Biochem Biophys 374:347–355, 2000.
61. Dirsch V, Wiemann W, Wagner H: Anti-inflammatory activity of triterpene quionone-methides and proanthocyanidins from the stem bark of Heisteria pallida Engl Pharm Pharmacol Lett 2:184–186, 1992.
62. Mao TK, Powell JJ, van de Water J, Keen CL, Schmitz HH, Gershwin ME: The influence of cocoa procyanidins on the transcription of interlukin-2 in peripheral blood mononuclear cells. Int J Immunother 15:23–29, 1999.
63. Ono K, Takahashi T, Kamei M, Mato T, Hashizume S, Kamiya S, Tsutsumi H: Effects of an aqueous extract of cocoa on nitric oxide production of macrophages activated by lipopolysaccaharide and interferon-γ. Nutrition 19:681–685, 2003.
64. Auger C, Gerain P, Laurent-Bichon F, Portet K, Bornet A, Caporiccio B, Cros G, Teissedre P-L, Rouanet J-M: Phenolics from commercialized grape extracts prevent early atherosclerotic lesions in hamsters by mechanisms other than antioxidant effect. J Agric Food Chem 52:5297–5302, 2004.
65. Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, Rice-Evans CA: Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Rad Biol Med 33:1693–1702, 2002.
66. Deprez S, Brezillon C, Rabot S, Philippe C, Mila I, Lapierre C, Scalbert A: Polymorphic proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. J Nutr 130:2733–2738, 2000.
67. Zhu QY, Holt RR, Lazarus SA, Orozco TJ, Keen CL: Inhibitory effects of cocoa flavanols and procyanidin oligomers on free radical-induced erythrocyte hemolysis. Exp Biol Med 227:321–329, 2002.
68. Ward NC, Croft KD, Puddey IB, Hodgson JM: Supplementation with grape seed polyphenols results in increased urinary excretion of 3-hydroxyphenylpropinoic acid, an important metabolite of proanthocyanidins in humans. J Agric Food Chem 52:5545–5549, 2004.
69. McKim SE, Konno A, Gabele E, Uesugi T, Froh M, Sies H, Thurman RG, Arteel GE: Cocoa extract protects against early alcohol-induced liver injury in the rat. Arch Biochem Biophy 406:40–46, 2002.
70. Crews FT, Collins MA, Dlugos C, Littleton J, Wilkins L, Neafsey EJ, Pentney R, Snell LD, Tabakoff B, Zou J, Noronha A: Alcoholinduced neurodegeneration: when, where and why? Alcohol Clin Expt Res 28:350–364, 2004.
71. Ming Z, Lu ZS, Gu JF, Sun LY, Liu XY: Co-treatment with ethanol enhances the toxicity of 6-hydroxydopamine. Neurosci Lett 367:250–253, 2004.
72. Hwang J, Sevanian A, Hodis HN, Ursini F: Synergistic inhibition of LDL oxidation by phytoestrogens and ascorbic acid. Free Rad Biol Med 29:79–89, 2000.
73. Burdette JE, Liu J, Lantvit D, Lim E, Booth N, Bhat KPL, Hedayat S, van Breemen RB, Constantinou AI, Pezzuto JM, Farnsworth NR, Bolton JL: Trifolium pratense (red clover) exhibits estrogenic effects in vivo in overectomized Sprague-Dawley rats. J Nutr 132:27–30, 2002.
74. Datla KP, Murray HE, Pillai AV, Gillies GE, Dexter DT: Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport 14:47–50, 2003.
75. Vila M, Jackson-Lewis V, Guegan C, Wu C, Teismann P, Choi D-K, Iieu K, Przedborski S: The role of glial cells in Parkinson’s disease. Curr Opin Neurol 14:483–489, 2001.
76. Liu B, Gao H-M, Hong J-S: Parkinson’s disease and exposure to infectious agents and pesticides and the occrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111:1065–1073, 2003.
77. Manthey JA, Grohmann K, Montanari A, Ash K, Manthey CL: Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-α expression by human monocytes. J Nat Prod 62:441–444, 1999.
78. Marakami A, Nakamura Y, Torikai K, Tanaka T, Koshiba T, Koshimizu K, Kuwahara S, Takahashi Y, Ogawa K, Yano M, Tokuda H, Nishino H, Mimaki Y, Sashida Y, Kitanaka S, Ohigashi H: Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res 60:5059–5066, 2000.
79. Morris PE, Olmstead LE, Howard-Carroll AE, Dickens GR, Goltz ML, Courtney-Shapiro C, Fanti P: In vitro and in vivo effects of genistein on murine alveolar macrophages TNF alpha production. Inflammation 23:231–239, 1999.
80. Atluru D, Jackson TM, Atluru S: Genistein, a selective protein tyrosine kinase inhibitor, inhibits interlukin-2 and leukotrine B4 production from human mononuclear cells. Clin Immonol Immunopathol 59:379–387, 1991.